RemeGen Co (HKSE:09995) Net Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. RemeGen Co's Net Income for the three months ended in Dec. 2023 was HK$0.0 Mil. RemeGen Co's Revenue for the three months ended in Dec. 2023 was HK$0.0 Mil. Therefore, RemeGen Co's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for RemeGen Co's Net Margin % or its related term are showing as below:

HKSE:09995' s Net Margin % Range Over the Past 10 Years
Min: -2384.46 Med: -135.26 Max: 19.4
Current: -99.35

HKSE:09995's Net Margin % is ranked better than
54.5% of 1033 companies
in the Biotechnology industry
Industry Median: -156.83 vs HKSE:09995: -99.35

RemeGen Co Net Margin % Historical Data

The historical data trend for RemeGen Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Net Margin % Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

19.40

-130.09

-140.43

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial									-156.76	-	-93.39	-	-105.59

Competitive Comparison of RemeGen Co's Net Margin %

For the Biotechnology subindustry, RemeGen Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Net Margin % falls into.

RemeGen Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

RemeGen Co's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1652.95	/	1177.048
	=	-140.43 %

RemeGen Co's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0
	=	%

RemeGen Co (HKSE:09995) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

RemeGen Co Net Margin % Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines